Figure 2.

Ibrutinib dose-dependently inhibits glycoprotein VI-mediated platelet aggregation, ATP secretion and Ca²⁺ mobilization. (A) (i) Representative traces showing the effect of increasing doses of in vitro ibrutinib incubated for 5 min with washed platelets at 4x10⁸/mL. (ii) Ibrutinib dose-response curves in washed platelets (n=7). (B) Representative traces showing the effect of increasing doses of in vitro ibrutinib incubated with washed platelets at 4x10⁸/mL for 5 min on (i) ATP secretion and (ii) Ca²⁺ mobilization in response to stimulation with CRP (10 μg/mL) for 180 s. (iii) Ibrutinib dose-response curves in washed platelets on ATP secretion (n=3) and Ca²⁺ mobilization (n=3). The dose-response curve for inhibition of washed platelet aggregation from (Aiii) is shown as a dotted line to enable comparison. Results are shown as mean ± SEM. All experiments were stimulated with CRP (10 μg/mL). For comparison of IC₅₀: ns = non-significant.